Skip to main content

408 publications

Name Date Type Actions

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Public releases

Clone of Buyback programs – April 2023

Monthly communication regarding buyback programs

Monthly communication regarding buyback programs

Buyback programs – May 2023

Monthly communication regarding buyback programs

Monthly communication regarding buyback programs

Buyback programs – June 2023

Monthly communication regarding buyback programs

Monthly communication regarding buyback programs

Buyback programs – March 2023

Monthly communication regarding buyback programs

Monthly communication regarding buyback programs

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Public releases

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

Public releases

First nine months 2022 sales: €405M

In line with year-end outlook

Public releases

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

Public releases , Half Year Report

2022 half-year results

This document has been prepared by Vetoquinol for the sole purpose of presenting the half-year results for the fiscal year 2022, on September 15, 2022.

Half Year Report